Takeda Recognized in the 2019 Dow Jones Sustainability World Index

Takeda Pharmaceutical Company Limited (“Takeda”) today announced that it has been named in the 2019 Dow Jones Sustainability World Index, achieving more than double the average overall industry score.

Also named in Dow Jones Sustainability Asia Pacific Index for 10th Consecutive Year
Achieved more than double the average pharmaceutical industry sustainability score
Demonstrated significant year-over-year growth in score for strategy to improve access to medicines

Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has been named in the 2019 Dow Jones Sustainability World Index, achieving more than double the average overall industry score. In addition, Takeda was named for the 10th consecutive year in the Dow Jones Sustainability Asia Pacific Index. The Dow Jones Sustainability Indices are an independent indication of the Company’s strong corporate environmental, social and governance (ESG) performance.


“Takeda’s commitment to creating and preserving value through environmental, social and governance initiatives is an important part of our role as a patient-centric and values-based global biopharmaceutical leader,” said Christophe Weber, President and CEO. “We understand the significance of sustainable business practices, and we are proud to be recognized for Takeda’s global impact and long-term commitment to building a brighter future.”


Takeda achieved more than double the average pharmaceutical industry sustainability score. Its strong scores in climate strategy and eco-efficiency support Takeda’s approach that a proactive environmental program focused on reducing environmental impacts leads to tangible economic benefits. Takeda also achieved double-digit year-over-year growth in its score for access to medicines – more than triple the industry average – based on its strategies to help strengthen evolving healthcare systems and tackle barriers that limit patient access.

About Takeda Pharmaceutical Company Limited


Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases, and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit www.takeda.com

In addition to Dow Jones World and Asia Pacific Indices, Takeda has been selected by multiple benchmark ESG indices and recognitions:

 

Name of
Index or Rating

Company/
Organization

Country

History of
Inclusion

FTSE4Good Developed Index

FTSE Russell

UK

15th consecutive year

MSCI ESG Leaders Index

MSCI

U.S.

10th consecutive year

Ethibel EXCELLENCE Investment
Register

Forum Ethibel

BEL

From July 2017

Prime Status

ISS-Oekom

GER

2nd consecutive year

Industry Mover Sustainability Yearbook
Award 2019

RobecoSAM

CHE

From February 2019

Global 100 Most Sustainable
Corporations in the World Index

Corporate Knights

CND

4th consecutive year


About Takeda’s Sustainable Value Report


Takeda’s annual Sustainable Value Report showcases how the company is addressing the world’s biggest challenges to sustainable development over the long-term. Data included are primarily non-financial, focusing on Takeda’s diverse CSR/ESG (sustainability) commitments, as well as how CSR/ESG priorities are inextricably linked to the company’s DNA. Takeda leverages such benchmarks as the international integrated reporting framework of the International Integrated Reporting Council (IIRC), United Nations Global Compact’s advanced level assessment criteria, and Global Reporting Initiative (GRI) Standards to create a comprehensive report that incorporates high standards of transparency and disclosure, targeting a broad range of stakeholders.
For more information, visit https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/.

Tags : #takeda #pharma #recognition #dowjones #sustainability #worldindex

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Harnessing AI for Early Alzheimer's Disease Diagnosis: IIT Indore's BreakthroughMay 06, 2024
Aurobindo Pharma's Bhiwadi Facility Under FDA Scrutiny: Understanding the ObservationsMay 06, 2024
Exploring the Role of Mediator Protein Complex in Cell Division: Implications for Disease ManagementMay 06, 2024
Akshay Tritiya Parna Mahotsav is to be held in the cityMay 04, 2024
Bharti Singh's Battle with Gallstones: Symptoms, Precautions, and Natural RemediesMay 04, 2024
Empowering Women's Health: New Mammogram GuidelinesMay 04, 2024
Rising Temperatures, Rising Risks: Addressing the Challenges of Heat StressMay 04, 2024
Gynoveda, India's First Ayurveda Fertility Company, Expands Reach with New Clinic in Pune, Set to Open 100 Clinics Across India by 2027May 03, 2024
Aptus Value Housing Finance India Limited, a leading Housing Finance Company has declared its financial results for the year ended March 31, 2024. FY 24 ResultsMay 03, 2024
TIPS FOR PREGNANCY CARE DURING SUMMERMay 03, 2024
The deadly intersection: TB and tobacco smoking co-epidemics in Indonesia Dr TARA SINGH BAM – CNSMay 03, 2024
Mintoak Expands Global Footprint with Strategic Leadership AppointmentsMay 03, 2024
The Future of Healthcare: 10 ways Telehealth is Improving Patient Outcomes and Reducing CostsMay 03, 2024
Understanding the Effects of a Keto Diet on Your Body: A One-Month JourneyMay 03, 2024
High Blood Pressure in Youth: A Precursor to Severe Heart ConditionsMay 03, 2024
High Blood Pressure in Youth: A Precursor to Severe Heart ConditionsMay 03, 2024
Microplastics in Human Brains: Understanding the Emerging Health ConcernMay 03, 2024
Federal Bank Wraps Up FY 24 With 24% Rise in Profit, highest NII, Maintains Robust Asset QualityMay 02, 2024